AstraZeneca's Faslodex receives FDA approval for new indication
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for a new indication of its Faslodex (fulvestrant) to treat women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advance…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Food and Drug Administration (FDA) | HER2 | Hormones | Pharmaceuticals | Women